Overview

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Status:
Completed

Trial end date:
2018-04-10

Target enrollment:

Participant gender:

Summary

SP0966 is an exploratory study to investigate safety and efficacy of Lacosamide (LCM) in children with epilepsy syndromes associated with generalized seizures. LCM will be added to current antiepileptic treatment.

Phase:

Phase 2

Details

Lead Sponsor:

UCB Pharma

Treatments:

Lacosamide